Radiopharmaceutical therapies have been a breakthrough cancer treatment for tumors resistant to cytotoxic chemotherapy and many new radiopharmaceutical agents are in active development.
Radiation oncology is playing an increasingly important role in theranostics—but building a successful program requires more than clinical interest alone.
Immunotherapy has transformed the care of patients with recurrent/metastatic head and neck cancer but integration into definitive management has been more challenging.
Surface guided radiation therapy (SGRT) is a widely adopted technology—used in more than 40% of U.S. radiation therapy clinics—and is now a cornerstone of efficient, high-quality treatment delivery and patient safety.
Through a series of complex clinical scenarios, this activity examines decision-making strategies, technical considerations, and outcome optimization in nonmalignant condition management.
This educational series explores the evolving role of radiation therapy in managing nonmalignant conditions, addressing current challenges, emerging evidence, and specialized applications in clinical practice.
This program is designed to address the needs of a community practice physician and includes disease site reviews, interactive case-based discussions, a strategic dialogue with the ASTRO CEO and a radiation oncology practice overview.
Low-dose radiotherapy (LDRT) is gaining attention as a novel therapeutic approach for central nervous system (CNS) pathologies with inflammatory components, including Alzheimer's disease (AD) and other neurodegenerative disorders.
Facebook
X
LinkedIn
Forward
